ABSTRACT
The present study was performed to determine the effect of combined intravenous and oral volume supplementation on the incidence of contrast-induced nephropathy [CIN] in patients undergoing percutaneous coronary intervention [PCI]. Consecutive patients [n = 958] receiving iomeprol 350 during PCI were evaluated prospectively for the development of CIN. All patients received protocol-defined intravenous and oral volume supplementation. CIN was defined as an increase in serum creatinine of at least 44 micromol/l within 48 h. Of the 958 patients enrolled in the study, 147 [15%] were diabetic and 107 [11%] had stage III renal disease. The average baseline glomerular filtration rate was 88 +/- 25 ml/min/1.73 m[2]. During the intervention an average of 238 +/- 86 ml of contrast medium was administered. CIN developed in 13 of 958 [1.4%; 95% confidence interval 0.6-2.1%] patients. The incidence of CIN was low even in predefined risk subgroups [women: 2.4%, diabetics: 2.7%, patients with stage III kidney disease: 6.5%]. The incidence of CIN is low when preprocedural fluid volume supplementation is used